<DOC>
	<DOCNO>NCT01336738</DOCNO>
	<brief_summary>B2611002 design study safe effective investigational medication ( PF-04991532 ) people Type 2 diabetes . Subjects study receive 1 5 treatment 3 month . One treatments sitagliptin approve drug , another treatment placebo , contain active ingredient .</brief_summary>
	<brief_title>Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Subjects type 2 diabetes stable dos background medicine management diabetes ; age 1870 year ; body mass index 22.5 45.5 kg/m2 Subjects type 1 diabetes , heart attack stroke past 6 month , uncontrolled blood pressure , significant kidney disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>safety efficacy study PF-04991532</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>